Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe).

Trial Profile

Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe).

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 30 Mar 2016

At a glance

  • Drugs Rituximab (Primary) ; Rituximab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms RIVITaLISe
  • Most Recent Events

    • 25 Mar 2016 Status changed from active, no longer recruiting to discontinued as efficacy on CSF biomarkers failed to reach criteria for continuation of the trial as per ClinicalTrials.gov record.
    • 02 Oct 2015 Planned End Date changed from 1 Sep 2017 to 1 Sep 2016, as reported by ClinicalTrials.gov.
    • 03 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top